AbbVie beats by $0.02, reports revs in-line; reaffirms FY17 EPS guidance (65.04)
- Reports Q1 (Mar) earnings of $1.28 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $1.26; revenues rose 9.7% year/year to $6.54 bln vs the $6.49 bln Capital IQ Consensus. Global HUMIRA sales increased 15.1 percent on a reported basis, or 15.8 percent operationally, excluding a 0.7 percent unfavorable impact from foreign exchange. In the U.S., HUMIRA sales grew 22.8 percent in the quarter. Internationally, HUMIRA sales grew 4.6 percent, excluding a 1.7 percent unfavorable impact from foreign exchange. First-quarter global IMBRUVICA net revenues were $551 million, with U.S. sales of $457 million and international profit sharing of $94 million for the quarter, reflecting growth of 44.7 percent.
- Co reaffirms guidance for FY17, sees EPS of $5.44-5.54, excluding non-recurring items, vs. $5.49 Capital IQ Consensus Estimate.